Faculty, Staff and Student Publications
Publication Date
12-1-2024
Journal
Trends in Immunology
DOI
10.1016/j.it.2024.11.007
PMID
39603891
PMCID
PMC13015198
PubMedCentral® Posted Date
3-26-2026
PubMedCentral® Full Text Version
Author MSS
Abstract
In the battle against cancer, researchers are exploring the use of engineered bacteria as living medicines. Redenti and colleagues demonstrate that Escherichia coli Nissle 1917 (EcN) can be engineered to deliver cancer neoantigen payloads, stimulating antigen-specific CD4+ and CD8+ T cells and mediating antitumor immunity in preclinical models of colorectal cancer and melanoma.
Keywords
Cancer Vaccines, Humans, Antigens, Neoplasm, Animals, Escherichia coli, Neoplasms, CD8-Positive T-Lymphocytes, Melanoma, CD4-Positive T-Lymphocytes, Immunotherapy
Published Open-Access
yes
Recommended Citation
Christopher D Johnston and Jennifer A Wargo, "Engineering Immunity: Bacterial Delivery of Cancer Neoantigen Vaccines" (2024). Faculty, Staff and Student Publications. 6765.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/6765
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons